Congressional Investigator Faults FDA Office of Chief Counsel
Executive Summary
A senior investigator for the House Energy and Commerce Committee testified at an April 29 hearing that FDA's Office of Chief Counsel had thwarted a Congressional investigation into heparin contamination in China. David Nelson said the OCC refused to provide documents relating to FDA's inspection process and would not let investigators interview OCC staff attorneys
You may also be interested in...
FDA’s Office of Chief Counsel Is Growing Its Ranks As It Amends Its Act
Tucked away on the sixth floor of the Parklawn Building in Rockville, FDA's Office of Chief Counsel is calm and quiet. Beneath the surface, however, there is a surge of activity. One of the main engines driving the agency, the 80-lawyer shop helps craft regulations, manages dozens of lawsuits and oversees every enforcement action
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.